Report cover image

Nuclear Medicine Market by Type [SPECT (Tc-99m, I-123, Ga-67), PET (F-18), Alpha Emitters, Beta Emitters (Y-90, Lu-177), Brachytherapy], Application (Oncology, Cardiology, Neurology), Procedure, End User (Imaging Center, Hospital), and Region – Global For

Publisher MarketsandMarkets
Published Jan 26, 2026
Length 536 Pages
SKU # MKMK20921786

Description

The global nuclear medicine market is projected to reach USD 21.01 billion by 2030, growing from USD 10.41 billion in 2025 at a CAGR of 15.1% during the forecast period. This projection is driven by the growing demand for diagnostic and therapeutic radiopharmaceuticals and medical radioisotopes in the oncology, cardiology, and neurology fields. Additionally, the increased utilization of targeted radionuclide therapies, growth in cyclotron and reactor-based production of radioisotopes, and enhanced availability of these products through nuclear pharmacy networks are enhancing the growth of the market. Moreover, there is a significant increase in the use of radiopharmaceuticals across the globe as new ones are constantly developed and approved by regulatory bodies. This increased use of radiopharmaceuticals is further driving the growth of the market.

“The hospitals segment is projected to account for the largest share during the forecast period.”

By end user, the hospitals segment is projected to account for the largest share of the nuclear medicine market during the forecast period. This projection is based on the capability of hospitals in preparing and administering radiopharmaceuticals through complex processes, available licensed facilities to deal with radioisotopes, and the presence of specialized nuclear medicine experts. Additionally, the presence of large volumes of patients, combined with diagnostic and therapeutic services, and well-established reimbursement systems in hospitals, is further expected to drive the growth of the segment in the coming years.

“The therapeutic applications segment is projected to register a higher growth than the diagnostic applications segment during the forecast period.”

The therapeutic applications segment is projected to register a higher growth than the diagnostics applications segment during the forecast period. This projection is driven by the rising application of targeted radiopharmaceutical therapies and radioisotopes in treating cancer, especially in theranostics. Increasing clinical efficacy of radionuclide therapies and growing regulatory approval and investment in the production of therapeutic radioisotopes are boosting the acceptance across healthcare providers.

“Asia Pacific is projected to witness the highest growth rate during the forecast period.”

Asia Pacific is projected to register the highest growth in the nuclear medicine market over the forecast period. This is due to the rising demand for radiopharmaceuticals and radioisotopes because of factors like increasing cancer prevalence, hospital facilities expansion, and growing access to nuclear medicine services. Additionally, the production of radioisotopes and the enhancement of regulatory infrastructure and supply chains by the governments are also increasing the growth of the markets in the region faster. Moreover, the growing healthcare spending and the rising awareness of early diagnosis and specific treatments are contributing to the rise in the number of nuclear medicine procedures.

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the authentication and brand protection marketplace.

The breakdown of primary participants is mentioned below:
  • By Company Type - Tier 1 – 64%; Tier 2 – 23%; and Tier 3 – 13%
  • By Designation - C Level – 35%; Director Level – 25%; and Others – 40%
  • By Region - North America – 44%; Europe – 23%; Asia Pacific – 28%; Latin America – 3%; Middle East & Africa – 2%
Key Players in the Nuclear Medicine Market

The key players operating in the nuclear medicine market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), NTP Radioisotopes SOC Ltd. (South Africa), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Isotope JSC (Russia), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), Institutes of Isotopes (Hungary), China Isotope & Radiation Corporation (China), and IRE Elit (Turkey).

Research Coverage

The report analyzes the nuclear medicine market and aims to estimate the market size and future growth potential of various market segments by type, application, volume assessment, end user, and region. The report provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.

This report provides insights into:

 Analysis of key drivers (Increasing incidence and prevalence of target conditions, development of alpha-radioimmunotherapy-based targeted cancer treatments, initiatives to reduce demand and supply gap of Mo-99), restraints (Short half-life of radiopharmaceuticals), opportunities (Use of radiopharmaceuticals in neurological applications, growth opportunities in emerging economies), challenges (Hospital budget cuts and high equipment costs) influencing the growth of the nuclear medicine market

 Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and product launches in the nuclear medicine market

 Market Development: Comprehensive information on the lucrative emerging markets (based on type, application, volume assessment, and end user) across regions

 Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the nuclear medicine market

 Competitive Assessment: In-depth assessment of market share, growth strategies, product offerings, and capabilities of the leading players [GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), and Lantheus Holdings, Inc. (US)] operating in the nuclear medicine market

Table of Contents

536 Pages
1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Regional Scope
1.3.3 Inclusions & Exclusions
1.3.4 Years Considered
1.4 Currency Considered
1.5 Limitations
1.6 Stakeholders
1.7 Summary Of Changes
2 Executive Summary
2.1 Market Highlights & Key Insights
2.2 Key Market Participants: Mapping Of Strategic Developments
2.3 Disruptive Trends In Nuclear Medicine Market
2.4 High-growth Segments
2.5 Regional Snapshot: Market Size, Growth Rate, And Forecast
3 Premium Insights
3.1 Nuclear Medicine Market Overview
3.2 North America: Nuclear Medicine Market, By Type & Country
3.3 Nuclear Medicine Market: Geographic Snapshot
3.4 Nuclear Medicine Market: Developed Vs. Emerging Economies
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Increasing Incidence And Prevalence Of Target Conditions
4.2.1.2 Rapid Expansion Of Radioligand & Targeted Radionuclide Therapy
4.2.1.3 Strategic Entry Of Large Pharma & Capital Inflows
4.2.1.4 Initiatives To Reduce Demand And Supply Gap Of Mo-99
4.2.2 Restraints
4.2.2.1 Short Half-life Of Radiopharmaceuticals
4.2.2.2 Structural Isotope Supply Fragility
4.2.3 Opportunities
4.2.3.1 Development Of Alpha-radioimmunotherapy-based Targeted Cancer Treatments
4.2.3.2 Use Of Radiopharmaceuticals In Neurological Applications
4.2.3.3 Growth Opportunities In Emerging Economies And Expanding Pet Infrastructure
4.2.4 Challenges
4.2.4.1 High Capital Intensity Of Nuclear Medicine Infrastructure And Hospital Budget Cuts
4.2.4.2 Workforce Shortage In Nuclear Medicine
4.3 Unmet Needs & White Spaces
4.4 Interconnected Markets & Cross-sector Opportunities
4.5 Strategic Moves By Tier-1/2/3 Players
5 Industry Trends
5.1 Porter’s Five Forces Analysis
5.1.1 Intensity Of Competitive Rivalry
5.1.2 Bargaining Power Of Suppliers
5.1.3 Bargaining Power Of Buyers
5.1.4 Threat Of Substitutes
5.1.5 Threat Of New Entrants
5.2 Macroeconomic Indicators
5.2.1 Introduction
5.2.2 Gdp Trends & Forecast
5.2.3 Trends In Global Healthcare Industry
5.2.4 Trends In Global Pharmaceutical Industry
5.3 Value Chain Analysis
5.4 Ecosystem Analysis
5.5 Pricing Analysis
5.5.1 Indicative Price Of Nuclear Medicine Products, By Type, 2024
5.5.2 Indicative Price Of Nuclear Medicine Products, By Region, 2024
5.6 Trade Analysis
5.6.1 Import Scenario For Hs Code 2844
5.6.2 Export Scenario For Hs Code 2844
5.6.3 Import Scenario For Hs Code 3002
5.6.4 Export Scenario For Hs Code 3002
5.7 Key Conferences & Events, 2026–2027
5.8 Trends/Disruptions Impacting Customers’ Businesses
5.9 Investment & Funding Scenario
5.10 Case Study Analysis
5.11 Impact Of 2025 Us Tariffs On Nuclear Medicine Market
5.11.1 Introduction
5.11.2 Key Tariff Rates
5.11.3 Price Impact Analysis
5.11.4 Impact On Country/Region
5.11.4.1 Us
5.11.4.2 Europe
5.11.4.3 Asia Pacific
5.11.5 Impact On End-use Industries
5.11.5.1 Hospitals
5.11.5.2 Diagnostic & Imaging Centers
5.11.5.3 Research & Academic Institutes
6 Strategic Disruptions Through Technology, Patents, And Digital & Ai Adoption
6.1 Key Emerging Technologies
6.1.1 Next-generation Radioligand Therapy & Theranostics
6.1.2 Radioisotope Production Technologies
6.1.3 High-specific-activity Radiolabeling And Chelation Chemistry
6.1.4 Gmp Hot-cell Manufacturing & Radiopharmaceutical Quality Control
6.1.5 Cold Kit & Generator Technologies
6.1.6 Decentralized Isotope Production & Advanced Radiopharmacy Systems
6.2 Complementary Technologies
6.2.1 Automated Radiotracer Synthesis & Dispensing Systems
6.2.2 Dosimetry & Treatment Planning Technologies
6.3 Adjacent Technologies
6.3.1 Target Discovery & Radioligand Design Platforms
6.3.2 Integrated Theranostic Workflows & Data Platforms
6.3.3 Ai-enabled Quantitative Imaging & Workflow Automation
6.4 Technology/Product Roadmap
6.5 Patent Analysis
6.5.1 Patent Publication Trends For Nuclear Medicine Market
6.5.2 Insights: Jurisdiction & Top Applicant Analysis
6.6 Future Applications
6.6.1 Precision Oncology & Theranostics Expansion
6.6.2 Personalized Radionuclide Therapy Using Dosimetry-guided Dosing
6.6.3 Early Disease Detection & Risk Stratification
6.6.4 Neurodegenerative & Neuroinflammatory Disorders
6.6.5 Inflammation, Infection, And Immune System Imaging
6.7 Impact Of Ai/Gen Ai On Nuclear Medicine Market
6.7.1 Introduction
6.7.2 Market Potential Of Ai/Gen Ai In Nuclear Medicine Market
6.7.3 Case Studies Related To Ai/Gen Ai Implementation
6.7.3.1 Clinical Validation Of Ai-enabled Standardization And Workflow Efficiency In Psma Pet Imaging For Prostate Cancer
6.7.4 Impact Of Ai/Gen Ai On Interconnected & Adjacent Ecosystems
6.7.4.1 Radiopharmacy, Manufacturing, And Quality Operations
6.7.4.2 Clinical Imaging, Dosimetry, And Treatment Planning Infrastructure
6.7.4.3 Hospital Systems, Regulatory Compliance, And Theranostic Data Platforms
6.7.5 User Readiness And Impact Assessment
6.7.5.1 User Readiness
6.7.5.1.1 User A: Hospitals
6.7.5.1.2 User B: Diagnostic & Imaging Centers
6.7.5.2 Impact Assessment
6.7.5.2.1 User A: Hospitals
6.7.5.2.1.1 Implementation
6.7.5.2.1.2 Impact
6.7.5.2.2 User B: Diagnostic & Imaging Centers
6.7.5.2.2.1 Implementation
6.7.5.2.2.2 Impact
7 Regulatory Landscape
7.1 Regional Regulations & Compliance
7.1.1 Regulatory Bodies, Government Agencies, And Other Organizations
7.1.2 Regulatory Framework
7.1.2.1 North America
7.1.2.2 Europe
7.1.2.3 Asia Pacific
7.1.2.4 Latin America
7.1.2.5 Middle East & Africa
7.1.3 Industry Standards
8 Customer Landscape & Buyer Behavior
8.1 Introduction
8.2 Decision-making Process
8.3 Buyer Stakeholders & Buying Evaluation Criteria
8.3.1 Key Stakeholders In Buying Process
8.3.2 Buying Criteria
8.4 Adoption Barriers & Internal Challenges
8.5 Unmet Needs From Various End-use Industries
8.5.1 Unmet Needs
8.5.2 End-user Expectations
8.6 Market Profitability
9 Nuclear Medicine Market, By Type
9.1 Introduction
9.2 Diagnostic Nuclear Medicine
9.2.1 Spect Radiopharmaceuticals
9.2.1.1 Tc-99m
9.2.1.1.1 Dominant Role Of Tc-99m In Spect To Boost Market Growth
9.2.1.2 I-123
9.2.1.2.1 Reduced Exposure To Radiation And Lower Risk Of Patients Developing Radiation-induced Cancer To Drive Demand
9.2.1.3 Tl-201
9.2.1.3.1 Most Commonly Used Substitute For Tc-99m In Cardiac Stress Tests To Support Market Growth
9.2.1.4 Ga-67
9.2.1.4.1 Long Half-life Of Ga-67 To Facilitate Easy Sales And Distribution
9.2.1.5 Other Spect Radiopharmaceuticals
9.2.2 Pet Radiopharmaceuticals
9.2.2.1 F-18
9.2.2.1.1 Advantages Such As Highly Accurate, Metabolism-based Cancer Imaging To Boost Demand
9.2.2.2 Rb-82
9.2.2.2.1 High Accuracy Offered By Rb-82 Isotopes To Support Market Growth
9.2.2.3 Other Pet Radiopharmaceuticals
9.3 Therapeutic Nuclear Medicine
9.3.1 Alpha Emitters
9.3.1.1 Ra-223
9.3.1.1.1 Rising Metastatic Prostate Cancer Burden And Demand For Bone-targeted, Outpatient Alpha Therapy To Drive Adoption
9.3.2 Beta Emitters
9.3.2.1 I-131
9.3.2.1.1 I-131 To Account For Largest Share Of Beta Emitters Market During Forecast Period
9.3.2.2 Y-90
9.3.2.2.1 Rising Incidence Of Liver Cancers And Hepatocellular Carcinoma To Propel Growth
9.3.2.3 Sm-153
9.3.2.3.1 Increasing Incidence Of Bone Metastasis To Drive Market
9.3.2.4 Lu-177
9.3.2.4.1 Rising Cancer Burden And Expanding Prrt Adoption To Fuel Growth
9.3.2.5 Other Beta Emitters
9.3.3 Brachytherapy Isotopes
9.3.3.1 I-125
9.3.3.1.1 I-125 To Account For Largest Share Of Brachytherapy Isotopes Market
9.3.3.2 Ir-192
9.3.3.2.1 Precise, High-dose Brachytherapy Across Multiple Cancers To Propel Market
9.3.3.3 Pd-103
9.3.3.3.1 Ability To Make Brachytherapy Permanent Implant Seeds For Early-stage Prostate Cancer To Drive Adoption
9.3.3.4 Cs-131
9.3.3.4.1 Growing Use Of Cs-131 In Gynecological Applications To Aid Growth
9.3.3.5 Other Brachytherapy Isotopes
10 Nuclear Medicine Market, By Application
10.1 Introduction
10.2 Diagnostic Applications
10.2.1 Spect Applications
10.2.1.1 Cardiology
10.2.1.1.1 Rising Global Cardiovascular Disease Burden And Expanding, Evidence-backed Cardiology Applications To Drive Growth
10.2.1.2 Bone Scans
10.2.1.2.1 High Precision Of Spect To Boost Adoption Of Bone Scans
10.2.1.3 Thyroid
10.2.1.3.1 Rising Demand For Combination Spect/Ct Therapy To Drive Market Growth
10.2.1.4 Pulmonary Scans
10.2.1.4.1 High Accuracy And Sensitivity Of Spect/Ct Pulmonary Imaging To Boost Market
10.2.1.5 Other Spect Applications
10.2.2 Pet Applications
10.2.2.1 Oncology
10.2.2.1.1 Increasing Incidence Of Cancer To Fuel Market Growth
10.2.2.2 Cardiology
10.2.2.2.1 Growing Preference For Fdg In Cardiac Imaging To Propel Market
10.2.2.3 Neurology
10.2.2.3.1 Increasing Incidence Of Ad, Epilepsy, And Parkinson’s Disease To Increase Adoption Of Pet Imaging
10.2.2.4 Other Pet Applications
10.3 Therapeutic Applications
10.3.1 Thyroid Indications
10.3.1.1 Increasing Prevalence Of Thyroid Disorders To Boost Market
10.3.2 Bone Metastasis
10.3.2.1 Introduction Of Novel Therapies For Bone Metastasis To Positively Impact Market Growth
10.3.3 Endocrine Tumors
10.3.3.1 Us To Dominate Therapeutic Nuclear Medicine Market For Endocrine Tumor Applications
10.3.4 Lymphoma
10.3.4.1 Development Of New Isotopes For Treatment Of Lymphoma To Present Huge Growth Opportunities
10.3.5 Other Therapeutic Applications
11 Nuclear Medicine Market: Procedural Volume Assessment
11.1 Introduction
11.2 Diagnostic Procedures
11.2.1 High Prevalence Of Cancer And Cardiac Diseases To Drive Market Growth
11.3 Therapeutic Procedures
11.3.1 Growing Demand For Non-invasive Methods To Support Market Growth
12 Nuclear Medicine Market, By End User
12.1 Introduction
12.2 Hospitals
12.2.1 Growing Volume Of Diagnostic Procedures To Drive Market Growth
12.3 Diagnostic & Imaging Centers
12.3.1 Growing Number Of Private Imaging Centers To Support Market Growth
12.4 Academic & Research Institutes
12.4.1 Increasing Collaborations Between Nuclear Imaging Companies And Academia To Propel Market Growth
12.5 Other End Users
13 Nuclear Medicine Market, By Region
13.1 Introduction
13.2 North America
13.2.1 Macroeconomic Outlook For North America
13.2.2 Us
13.2.2.1 Us To Dominate North American Nuclear Medicine Market During Forecast Period
13.2.3 Canada
13.2.3.1 Increasing Initiatives For Medical Isotope Development To Support Market Growth
13.3 Europe
13.3.1 Macroeconomic Outlook For Europe
13.3.2 Germany
13.3.2.1 Well-established Healthcare System To Drive Market Growth
13.3.3 France
13.3.3.1 Rising Incidence Of Diseases Such As Cancer, Alzheimer’s, And Parkinson’s Disease To Favor Market Growth
13.3.4 Uk
13.3.4.1 Growing Demand For Diagnostic Imaging And Growing Awareness To Drive Market Growth
13.3.5 Italy
13.3.5.1 Aging Demographics, High Procedure Volumes, Increasing Cancer Incidence, And Domestic Isotope Self-sufficiency To Fuel Growth
13.3.6 Spain
13.3.6.1 Rising Disease Prevalence, Regulatory Modernization, And Targeted Radioligand Expansion To Create Supportive Environment
13.3.7 Rest Of Europe
13.4 Asia Pacific
13.4.1 Macroeconomic Outlook For Asia Pacific
13.4.2 Japan
13.4.2.1 Japan To Dominate Apac Nuclear Medicine Market
13.4.3 China
13.4.3.1 Increasing Nuclear Medicine Infrastructure And Growing Prevalence Of Chronic Diseases To Augment Market
13.4.4 India
13.4.4.1 Rising Cancer And Cardiovascular Disease Burden And Rapid Expansion Of Nuclear Medicine Infrastructure To Boost Market
13.4.5 South Korea
13.4.5.1 Accelerating Pet Utilization And Maturing Domestic Rpt Innovation Ecosystem To Augment Market
13.4.6 Australia
13.4.6.1 Rising Cancer Prevalence, High Pet Penetration, And Growing Domestic Isotope Production To Support Growth
13.4.7 Rest Of Asia Pacific
13.5 Latin America
13.5.1 Macroeconomic Outlook For Latin America
13.5.2 Brazil
13.5.2.1 Rising Cancer Incidence And Expanding Imaging Infrastructure To Drive Market
13.5.3 Mexico
13.5.3.1 Rising Cancer And Cardiovascular Disease Burden And Expanding Private-sector Pet Access To Drive Market
13.5.4 Rest Of Latin America
13.6 Middle East & Africa
13.6.1 Macroeconomic Outlook For Middle East & Africa
13.6.2 Gcc Countries
13.6.2.1 Growing Healthcare Needs And Favorable Government Support To Boost Market
13.6.3 Rest Of Middle East & Africa
14 Competitive Landscape
14.1 Overview
14.2 Key Player Strategies/Right To Win
14.2.1 Overview Of Strategies Adopted By Key Players In Nuclear Medicine Market
14.3 Revenue Analysis, 2020–2024
14.4 Market Share Analysis, 2024
14.5 Brand/Product Comparison
14.6 Company Valuation & Financial Metrics
14.6.1 Financial Metrics
14.6.2 Company Valuation
14.7 Company Evaluation Matrix: Key Players, 2024
14.7.1 Stars
14.7.2 Emerging Leaders
14.7.3 Pervasive Players
14.7.4 Participants
14.7.5 Company Footprint: Key Players, 2024
14.7.5.1 Company Footprint
14.7.5.2 Region Footprint
14.7.5.3 Type Footprint
14.7.5.4 Application Footprint
14.8 Company Evaluation Matrix: Startups/Smes, 2024
14.8.1 Progressive Companies
14.8.2 Responsive Companies
14.8.3 Dynamic Companies
14.8.4 Starting Blocks
14.8.5 Competitive Benchmarking: Startups/Smes, 2024
14.8.5.1 Detailed List Of Key Startups/Smes
14.8.5.2 Competitive Benchmarking Of Startups/Smes
14.9 Competitive Scenario
14.9.1 Product Approvals
14.9.2 Deals
14.9.3 Expansions
14.9.4 Other Developments
15 Company Profiles
15.1 Key Players
15.1.1 Novartis Ag
15.1.1.1 Business Overview
15.1.1.2 Products Offered
15.1.1.3 Recent Developments
15.1.1.3.1 Product Approvals
15.1.1.3.2 Deals
15.1.1.3.3 Expansions
15.1.1.4 Mnm View
15.1.1.4.1 Right To Win
15.1.1.4.2 Strategic Choices
15.1.1.4.3 Weaknesses & Competitive Threats
15.1.2 Lantheus Holdings, Inc.
15.1.2.1 Business Overview
15.1.2.2 Products Offered
15.1.2.3 Recent Developments
15.1.2.3.1 Deals
15.1.2.4 Mnm View
15.1.2.4.1 Right To Win
15.1.2.4.2 Strategic Choices
15.1.2.4.3 Weaknesses & Competitive Threats
15.1.3 Ge Healthcare
15.1.3.1 Business Overview
15.1.3.2 Products Offered
15.1.3.3 Recent Developments
15.1.3.3.1 Product Approvals
15.1.3.3.2 Deals
15.1.3.3.3 Expansions
15.1.3.3.4 Other Developments
15.1.3.4 Mnm View
15.1.3.4.1 Right To Win
15.1.3.4.2 Strategic Choices
15.1.3.4.3 Weaknesses & Competitive Threats
15.1.4 Curium
15.1.4.1 Business Overview
15.1.4.2 Products Offered
15.1.4.3 Recent Developments
15.1.4.3.1 Product Approvals & Enhancements
15.1.4.3.2 Deals
15.1.4.3.3 Expansions
15.1.4.3.4 Other Developments
15.1.4.4 Mnm View
15.1.4.4.1 Right To Win
15.1.4.4.2 Strategic Choices
15.1.4.4.3 Weaknesses & Competitive Threats
15.1.5 Telix Pharmaceuticals Limited
15.1.5.1 Business Overview
15.1.5.2 Products Offered
15.1.5.3 Recent Developments
15.1.5.3.1 Product Approvals
15.1.5.3.2 Deals
15.1.5.3.3 Other Developments
15.1.5.4 Mnm View
15.1.5.4.1 Right To Win
15.1.5.4.2 Strategic Choices
15.1.5.4.3 Weaknesses & Competitive Threats
15.1.6 Siemens Healthineers
15.1.6.1 Business Overview
15.1.6.2 Products Offered
15.1.6.3 Recent Developments
15.1.6.3.1 Deals
15.1.6.3.2 Other Developments
15.1.7 China Isotope & Radiation Corporation
15.1.7.1 Business Overview
15.1.7.2 Products Offered
15.1.7.3 Recent Developments
15.1.7.3.1 Other Developments
15.1.8 Bayer Ag
15.1.8.1 Business Overview
15.1.8.2 Products Offered
15.1.8.3 Recent Developments
15.1.8.3.1 Deals
15.1.9 Bracco Imaging S.P.A.
15.1.9.1 Business Overview
15.1.9.2 Products Offered
15.1.9.3 Recent Developments
15.1.9.3.1 Product Approvals
15.1.9.3.2 Deals
15.1.9.3.3 Other Developments
15.1.10 Cardinal Health
15.1.10.1 Business Overview
15.1.10.2 Products Offered
15.1.10.3 Recent Developments
15.1.10.3.1 Deals
15.1.11 Jubilant Pharmova Limited
15.1.11.1 Business Overview
15.1.11.2 Products Offered
15.1.11.3 Recent Developments
15.1.11.3.1 Product Approvals
15.1.11.3.2 Deals
15.1.11.3.3 Other Developments
15.1.12 Eli Lilly And Company
15.1.12.1 Business Overview
15.1.12.2 Products Offered
15.1.12.3 Recent Developments
15.1.12.3.1 Deals
15.1.12.3.2 Other Developments
15.1.13 Bwxt Medical Ltd.
15.1.13.1 Business Overview
15.1.13.2 Products Offered
15.1.13.3 Recent Developments
15.1.13.3.1 Product Approvals
15.1.14 Ntp Radioisotopes Soc Ltd. (A Subsidiary Of South African Nuclear Energy Corporation)
15.1.14.1 Business Overview
15.1.14.2 Products Offered
15.1.14.3 Recent Developments
15.1.14.3.1 Deals
15.1.15 Eckert & Ziegler
15.1.15.1 Business Overview
15.1.15.2 Products Offered
15.1.15.3 Recent Developments
15.1.15.3.1 Product Approvals
15.1.15.3.2 Deals
15.1.15.3.3 Expansions
15.1.16 Isotope Jsc
15.1.16.1 Business Overview
15.1.16.2 Products Offered
15.1.16.3 Recent Developments
15.1.16.3.1 Deals
15.1.16.3.2 Other Developments
15.1.17 Pdradiopharma Inc.
15.1.17.1 Business Overview
15.1.17.2 Products Offered
15.1.17.3 Recent Developments
15.1.17.3.1 Product Launches & Approvals
15.1.17.3.2 Deals
15.1.17.3.3 Expansions
15.1.18 Itm Isotope Technologies Munich Se
15.1.18.1 Business Overview
15.1.18.2 Products Offered
15.1.18.3 Recent Developments
15.1.18.3.1 Product Approvals
15.1.18.3.2 Deals
15.1.18.3.3 Expansions
15.1.18.3.4 Other Developments
15.1.19 Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów – Polatom
15.1.19.1 Business Overview
15.1.19.2 Products Offered
15.1.19.3 Recent Developments
15.1.19.3.1 Deals
15.1.20 Ansto
15.1.20.1 Business Overview
15.1.20.2 Products Offered
15.1.20.3 Recent Developments
15.1.20.3.1 Deals
15.1.20.3.2 Other Developments
15.2 Other Players
15.2.1 Shine Technologies, Llc
15.2.2 Isotopia Molecular Imaging Ltd.
15.2.3 Institute Of Isotopes
15.2.4 Global Medical Solutions
15.2.5 Isotex Diagnostics
16 Research Methodology
16.1 Research Data
16.2 Research Approach
16.2.1 Secondary Research
16.2.1.1 Key Data From Secondary Sources
16.2.2 Primary Research
16.2.2.1 Primary Sources
16.2.2.2 Key Data From Primary Sources
16.2.2.3 Breakdown Of Primaries
16.2.2.4 Insights From Primary Experts
16.3 Research Methodology Design
16.4 Market Size Estimation
16.4.1 Approach 1: Revenue Share Analysis (Bottom-up Approach – Supply-side Analysis)
16.4.2 Approach 2: Secondary Data & Primary Interviews
16.4.3 Approach 3: Segmental Market Size Assessment
16.4.4 Approach 4: Top-down Approach
16.4.5 Growth Forecast
16.4.6 Geographic Market Assessment (By Region And Country)
16.5 Market Breakdown & Data Triangulation
16.6 Study Assumptions
16.7 Research Limitations
16.7.1 Methodology-related Limitations
16.7.2 Scope-related Limitations
16.8 Risk Assessment
17 Appendix
17.1 Discussion Guide
17.2 Knowledgestore: Marketsandmarkets’ Subscription Portal
17.3 Customization Options
17.4 Related Reports
17.5 Author Details

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us